Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

850103P

Avanti

17:1 Lyso PI

1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder

Sinonimo/i:

PI(17:1(10Z)/0:0); 110718

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C26H52NO12P
Numero CAS:
Peso molecolare:
601.66
Codice UNSPSC:
51191904
NACRES:
NA.25

Saggio

>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)

Stato

powder

Confezionamento

pkg of 1 × 100 μg (with stopper and crimp cap (850103P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850103P-500ug))

Produttore/marchio commerciale

Avanti Research - A Croda Brand 850103P

Tipo di lipide

phosphoglycerides

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

Stringa SMILE

[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCC/C=C\CCCCCC)=O.[NH4+]

InChI

1S/C26H49O12P.H3N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(28)36-17-19(27)18-37-39(34,35)38-26-24(32)22(30)21(29)23(31)25(26)33;/h7-8,19,21-27,29-33H,2-6,9-18H2,1H3,(H,34,35);1H3/b8-7-;/t19-,21-,22-,23+,24-,25-,26-;/m1./s1
VFLBJIAFDLNWCY-SNLSZFGJSA-N

Descrizione generale

Lysophosphatidylinositol (LPI), a degradation product of phosphatidylinositol (PI) is a lysophospholipid subspecies, which carries inositol in its head group.

Applicazioni

17:1 Lyso PI (1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol)) has been used as an internal standard in LC-MS of mice brain lipidomic analysis. It may be used as internal standard in for the analysis of lysophosphatidylinositols (LPIs) in mice using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS) and in the quantification of lysoPI (LPI) in livers of chronic high-fat diet (HFD)-fed WT and KO mice using liquid chromatography with tandem mass spectrometry (LC-MS-MS) system.

Azioni biochim/fisiol

Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.
Lysophosphatidylinositol (LPI) serve as a bioactive lysophospholipid mediator. It favors mitogenic activity in quiescent fibroblasts. LPI has the ability to block hippocampal neuronal death in conditions of forebrain ischemia.

Confezionamento

2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-100ug)
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-500ug)

Note legali

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

No data available

Punto d’infiammabilità (°C)

No data available


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

15:0-18:1-d7-PI Avanti Research™ - A Croda Brand

Avanti

791641C

15:0-18:1-d7-PI

17:0 Lyso PA 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt), powder

Avanti

857127P

17:0 Lyso PA

18:1-d7 Lyso PC Avanti Research™ - A Croda Brand

Avanti

791643C

18:1-d7 Lyso PC

18:0 Lyso PI 1-stearoyl-2-hydroxy-sn-glycero-3-phosphoinositol (ammonium salt), powder

Avanti

850104P

18:0 Lyso PI

GPC-d9 Avanti Research™ - A Croda Brand

Avanti

100403X

GPC-d9

Tsukasa Yagi et al.
Cancers, 12(1) (2020-01-01)
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer
Jordon M Inloes et al.
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.